Irving, Texas (December 10, 2007) –RBC Life Sciences (OTCBB: RBCL) today announced that its Board of Directors has appointed John W. Price to the position of President of the company and member of the Board of Directors.
"We feel very fortunate to obtain the leadership of an executive whose background is so perfectly suited to the entire business spectrum of RBC, both domestically and internationally," stated Clinton Howard, Founder and CEO of RBC Life Sciences. "Currently, over 50 percent of our business is outside North America, and John's experience in international business should help us to further expand overseas. Additionally, I feel that our subsidiary, MPM Medical, will benefit substantially from John's in-depth experience in marketing of medical device products."
Prior to joining RBC Life Sciences, Mr. Price served as a senior executive for two major companies that market nutritional supplements similar to the core business of RBC. Additionally, Mr. Price led a successful management consulting company and spent 17 years as a senior officer at Eli Lilly, five years of which he supervised the company's branch office in Italy.
"As a triathlon athlete and Second Degree Black Belt, John has practiced all of his adult life the healthy nutrition and exercise that our company promotes. His community service work as a member of the review Board of the Boy Scouts of America Eagle Scout program is consistent with RBC's commitment to social responsibility and community service. Additionally, John is a retired Commander in the United States Navy and is fluent in several foreign languages," concluded Mr. Howard.
RBC Life Sciences develops, manufactures and markets skin care products and food supplements providing nutrients often found to be low or missing in modern diets. All products are tested for quality assurance in-house, and by outside independent laboratories, to comply with regulations in the U.S. and in more than thirty countries in which the products are distributed.
MPM Medical, a wholly owned subsidiary of RBC, develops and markets proprietary prescription and nonprescription products for wound and pain management, sold through medical-surgical dealers to nursing homes, hospitals and cancer clinics.
This press release is attached
The statements above, other than statements of historical fact, may be forward‑looking. Actual events will be dependent upon a number of factors and risks including but not limited to changes in plans by the Company's management, delays or problems in production, changes in the regulatory process, changes in market trends, and a number of other factors and risks described from time to time in the Company's filings with the Securities and Exchange Commission.
For Further Information:
Jeff Elliott
Halliburton Investor Relations
(972) 458-8000
jelliott@halliburtonir.com
search blogs
share it
blog it
